Modality
mAb
MOA
STINGag
Target
IL-23
Pathway
Autophagy
Bladder CaGastric Ca
Development Pipeline
Preclinical
~Feb 2019
→ ~May 2020
Phase 1
~Aug 2020
→ ~Nov 2021
Phase 2
Feb 2022
→ Oct 2028
Phase 2Current
NCT05690416
1,759 pts·Bladder Ca
2022-02→2028-10·Terminated
1,759 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-262.6y awayPh3 Readout· Bladder Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Termina…
Catalysts
Ph3 Readout
2028-10-26 · 2.6y away
Bladder Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05690416 | Phase 2/3 | Bladder Ca | Terminated | 1759 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Tezecilimab | Regeneron | Approved | IL-23 |